The present study was designed to compare elective transjugular intrahepatic portosystemic shunts (TIPS) and endoscopic sclerotherapy (EST) in terms of their efficacy in preventing recurrent bleeding from gastro-oesophageal varices in patients with advanced liver cirrhosis and portal hypertension. Of 96 patients with at least three gastro-oesophageal variceal rebleeds, 50 were treated with elective TIPS and 46 with EST. Recurrent variceal bleeding was significantly more frequent in patients receiving EST treatment compared with those receiving TIPS (45.7% versus 6.3%, respectively). Cumulative 1-and 4-year survival in the TIPS group was 83.0% and 73.5%, respectively, compared with 69.8% and 39.8% in the EST group, respectively. The rate of portosystemic encephalopathy was 33.3% in the TIPS group and 37.0% in the EST group. Elective TIPS was more effective than EST in the prevention of gastro-oesophageal variceal rebleeding in cirrhotic patients, it improved survival and it was associated with a similar rate of portosystemic encephalopathy.
Introduction
Bleeding from gastro-oesophageal varices is the most common life-threatening complication of cirrhosis of the liver. The first rebleeding and frequently recurring bleeding episodes are associated with high mortality rates. 1 -4 Rebleeding has been prevented by reducing portal venous pressure using βblockers, as well as by portacaval shunting, placement of a transjugular intrahepatic portosystemic shunt (TIPS) and endoscopic interruption of blood flow through varices by sclerotherapy (EST) or varix ligation (EVT). 1 -3 Pharmacological therapy with β-blockers and endoscopic treatments are the most widely used modalities. They are, however, not fully effective, since the average rebleeding rate with these treatments is about 50%. 1, 2, 4, 5 TIPS is a percutaneous interventional radiological procedure that P Popovič, B Štabuc, P Skok et al.
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involves the creation of a shunt between the hepatic vein and an intrahepatic branch of the portal vein, thereby decompressing the portal venous system. 6 Currently, surgical procedures and TIPS placement are only indicated in patients with bleeding that is refractory to pharmacological and endoscopic control or stabilization before liver transplantation. 7 -11 The precise application of TIPS among the various treatment alternatives for variceal rebleeding is not yet well defined. Thus, the purpose of the present study was to compare elective TIPS and EST in terms of their efficacy in preventing recurrent bleeding from gastro-oesophageal varices in patients with advanced liver cirrhosis and portal hypertension.
Patients and methods

PATIENT SELECTION AND STUDY DESIGN
This retrospective study included patients with liver cirrhosis and portal hypertension who were admitted to the University Medical Centre Ljubljana, Ljubljana, Slovenia, from April 1994 to January 2000 with an episode of gastro-oesophageal variceal rebleeding and who underwent routine treatment and were observed according to a predefined protocol. The study protocol was approved by the Medical Ethics Committee at the Slovenian Ministry of Health. Informed consent was not required because this was an (retrospective) observational study of routine treatments.
The inclusion criteria were: (i) Child-Pugh score ≥ 6; (ii) at least three gastrooesophageal variceal rebleeds;
(iii) experience of elective pharmacological (βblockers) and ESV prevention of recurrent variceal bleeding; and (iv) experience of elective TIPS placement in patients with bleeding refractory to pharmacological and endoscopic control. Exclusion criteria included: (i) chronic occlusion of the portal vein; (ii) hepatocellular carcinoma or other malignant lesions; (iii) acute alcoholic hepatitis; and (iv) age > 75 years. Recurrent variceal bleeding was defined as any episode of upper gastrointestinal bleeding that occurred after the first sclerotherapy session or subsequently between scheduled treatment sessions. The patients in the TIPS group were included in the study from the time of the TIPS procedure and the patients in the EST group were included from the time of discharge from hospital. Patients in both groups were followed-up either until the last control examination, until death, or until liver transplantation, as described in a later section (below).
PROCEDURES
The TIPS technique has been extensively described elsewhere so is only briefly discussed here. 6,12 -14 In the EST group, endoscopic treatment was performed via paravariceal and intravariceal injection of 1% polydocanol (Resinag, Zug, Switzerland). Histoacryl adhesive (B Braun Medical, Melsungen, Switzerland), used in the same proportion as polydocanol, was injected directly into the varices. Usually, the bleeding varix was injected with 1 -2 ml of the solution. Patients received antibiotic prophylaxis prior to and after EST, and octreotide (1.2 mg/24 h for 3 -5 days) after the procedure. Subsequent sclerotherapy was undertaken at 3 -4-week intervals on an outpatient basis until the varices were eradicated. After variceal obliteration, surveillance endoscopy was performed at 6 months and then annually to identify patients in whom varices had recurred. Repeat injection sclerotherapy was performed whenever residual or recurrent varices were identified during surveillance endoscopy. All patients in the EST group received oral propranolol twice daily, starting at 40 mg/day and increasing to a maximum of 60 mg/day, according to the target reduction of pulse rate. The extent to which pulse rate was controlled was assessed during the follow-up visits and, at the same visits, complications associated with propranolol intake were assessed by patient interview.
FOLLOW-UP OBSERVATIONS
Follow-up observations included clinical assessment, upper gastrointestinal endoscopy, ultrasound examination of the abdomen and examination of shunt flow using colour duplex sonography. A clinical examination was performed in all patients every 3 months. Portosystemic encephalopathy (PSE) was evaluated by assessment of mental status and by measurement of serum ammonia level. Procedure-related PSE was defined as new, clinically significant PSE requiring the initiation of treatment in a patient with no previous history of PSE, or the worsening of pre-existing clinically significant PSE requiring either hospitalization or an increase in therapy administered on an outpatient basis within 2 years of the procedure. Endoscopy was performed every 6 months in all patients and EST was repeated if rebleeding or reappearance of varices occurred. Rebleeding was defined as endoscopically-confirmed variceal bleeding, independent of its severity. A baseline colour duplex ultrasound examination of the TIPS was performed within 24 h of its placement. Shunt patency was re-assessed at discharge and the result served as a reference value for follow-up examinations. Routine surveillance examinations were performed at 3-month intervals for the first year, and at 6-month intervals for the second and subsequent years. If a patient developed recurrent symptoms, variceal bleeding and/or ascites, the TIPS was examined by ultrasound. The ultrasound criteria for shunt dysfunction included: flow of < 60 cm/s or > 120 cm/s along the entire stent, or the absence of flow or reversal of intrahepatic portal flow direction in comparison with previous ultrasound images obtained after TIPS placement. All suspected shunt abnormalities were confirmed by venography and portosystemic pressure gradient measurements. Revision of the stent was performed when occlusion or stenosis was seen in angiography and when the portosystemic gradient was elevated, despite normal angiographic findings.
STATISTICAL ANALYSIS
Collected data were coded, tabulated, P Popovič, B Štabuc, P Skok et al.
Treatment of recurrent variceal bleeding
processed and analysed using the SPSS ® statistical package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The results are presented in graphical, tabular and numerical form as mean ± SD. Statistical analysis of demographic and clinical data between the groups used the t-test, χ 2 -test and Mann-Whitney U-test (Wilcoxon's test). Data for cumulative survival, variceal rebleeding episodes, development or deterioration of hepatic encephalopathy and impaired shunt patency were analysed using the Kaplan-Meier method and the log rank test. Survival was calculated as the period from enrolment in the study until death, liver transplantation or the end of the study. Statistically significant variables determined by univariate analysis were included in a multivariate analysis which used the Cox regression model to determine the influence of independent prognostic factors on survival, impaired shunt patency, rebleeding and occurrence of PSE. A P-value < 0.05 was considered to be statistically significant.
Results
CLINICAL DATA
There were 96 patients enrolled in the study. Of these, 50 patients had elective TIPS and 46 were treated only by EST. The TIPS patients were included in the study at the time of the TIPS procedure, which was 7 -35 (mean 25) days after the last bleeding episode. The EST patients were included in the study at the time of their discharge from hospital, which was 12 -16 (mean 13) days after the last bleeding episode. The mean ± SD follow-up period was 35.5 ± 19.6 months in the TIPS group and 28.6 ± 9.3 months in the EST group.
Both groups were similar at the time of entry into the study with regard to sex, age, aetiology of liver cirrhosis, Child-Pugh classification, number of previous episodes of variceal bleeding, previous encephalopathy, previous ascites and site of bleeding (Table  1) . Following TIPS and EST, liver transplantation was performed in four patients (three TIPS patients and one EST patient). The mean ± SD interval between the procedure and liver transplantation in the TIPS patients was 9.16 ± 2.75 months (range 5.8 -12.6 months) and in the EST patient it was 8 months.
TIPS PROCEDURE
The TIPS procedure, performed under general anaesthesia in all patients, was performed successfully in 48 of the 50 patients (96.0%). The two failures were due to an inability to puncture the portal vein. Wallstent metallic endoprostheses 12 mm in diameter and 60 -80 mm in length, and a dilatation balloon 10 -12 mm in diameter were used in all patients. The mean procedure time was 2 h (range 1.5 -4 h). Mean ± SD portal pressures before and after stenting were 23.9 ± 4.4 mmHg and 14.2 ± 2.8 mmHg, respectively, and the portosystemic pressure gradient decreased from 18.8 ± 5.6 mmHg to 9.6 ± 3.3 mmHg.
REBLEEDING
A significantly higher number of patients had rebleeding episodes in the EST group (21 patients, 45 .7%) than in the TIPS group (three patients, 6.3%; P = 0.001; χ 2 -test). Seven of the 21 patients (33.3%) treated by EST developed recurrent bleeding episodes within the first month and 17 of the 21 (81.0%) developed within the first year following EST. Fifteen patients bled from oesophageal varices, three from gastric and three from oesophagogastric varices. The mean interval between EST and recurrent bleeding was 6.6 months (range 11 days -25 months). Rebleeding in the three TIPS patients occurred due to shunt malfunction: P Popovič, B Štabuc, P Skok et al. Treatment of recurrent variceal bleeding two bled from gastric varices and one from oesophageal varices. The mean interval between TIPS and rebleeding was 19 months (range 5 -50 months). The probability of being free of variceal rebleeding during the first and fourth years of follow-up was significantly higher in TIPS than EST patients (92.4% versus 59.5% and 82.6% versus 40.6%, respectively; P = 0.03) ( Fig. 1 ). Multivariate Cox regression analysis showed that considering treatment modality, age, bilirubin, albumin, alanine transaminase, Child-Pugh classification, sex, aetiology of liver cirrhosis and platelet count, only EST treatment was an independent predictor of variceal rebleeding during follow-up (P = 0.001; Table 2 ).
SURVIVAL
Cumulative survival in the TIPS group was 83.0% after 1 year and 73.5% after 4 years whereas, in the EST group, it was 69.8% after 1 year and 39.8% after 4 years (Fig. 2) ; the difference was statistically significant between the two groups (P = 0.013, log-rank; P = 0.024, Wilcoxon's test). In the TIPS group, the main cause of death was liver failure whereas, in the EST group, it was variceal rebleeding. Two patients died within 30 days of TIPS, one because of liver failure and the other because of bleeding from a pseudoaneurysm of the thoracoabdominal aorta. There were six deaths within 30 days after EST, all of them due to variceal rebleeding. Cumulative survival in the TIPS group after 30 days was 95.8% and in the Mortality rates of patients with comparable grades of liver disease following TIPS were: 4.2% (n = 2) for Child-Pugh class A, 8.3% (n = 4) for Child-Pugh class B, and 14.6% (n = 7) for Child-Pugh class C; and following EST the rates were 2.2% (n = 1) for Child-Pugh class A, 28.3% (n = 13) for Child-Pugh class B, and 15.2% (n = 7) for Child-Pugh class C. After 3 years, the cumulative survival rates in the TIPS group for Child-Pugh A, B and C patients were 81.7%, 85.5%, 54.2%, respectively, and in the EST group they were 86.2%, 36.0%, 39.3%, respectively. There were no significant differences in mortality rates between the TIPS and EST groups in the Child-Pugh A and C classifications, however in Child-Pugh class B, the difference between the two groups was statistically significant (P = 0.0025; Wilcoxon's test).
Multivariate analysis Cox regression analysis included treatment modality, age, sex, aetiology of liver cirrhosis, bilirubin, alanine transaminase, albumin, ascites, platelet count and Child-Pugh classification and the analysis showed that EST treatment (P = 0.031) and age of > 65 years (P = 0.022) were significant independent predictors of death; Child-Pugh class C almost reached statistical significance as an independent predictor of death (P = 0.051) ( Table 3) .
COMPLICATIONS
In all, 16 patients (33.3%) in the TIPS group and 17 patients (37.0%) in the EST group developed clinically evident PSE (no statistically significant between-group difference). The incidence of new or worsening PSE was less common in the EST group than in the TIPS group (2.2% versus 8.2%, respectively), but the difference was not statistically significant. Patients with PSE were treated conservatively. Complications within 30 days of TIPS that were attributed to the procedure occurred in eight (16.7%) Early shunt dysfunction occurred in one TIPS patient in whom the stent was placed too high and did not reach far enough into the portal vein; insertion of another stent was required. Late shunt dysfunction was noted by ultrasound or clinically in nine (18.8%) TIPS patients; five patients were asymptomatic and four patients presented with clinical symptoms (variceal rebleeding in two patients and ascites). Reintervention was attempted in seven patients and was successful in six; reintervention was unsuccessful in one patient with hepatic vein stenosis. In four patients, reduction in transshunt flow was due to stenosis of the hepatic veins; in three of these cases shunt patency was restored by stent placement and in the other case shunt patency was restored by dilation only. One patient with stenosis of the central shunt portion was managed by dilation of the narrowed segment and placement of stents. In one patient, shunt obstruction was due to increased bile and mucine secretion into the shunt (TIPS-biliary fistula). After aspiration thrombectomy, a stent graft was inserted to prevent bile secretion. The mean interval between the TIPS procedure and additional reinterventions was 11.2 months. Two patients died prior to re-intervention due to recurrent variceal rebleeding and liver failure.
One year after the procedure, primary patency and primary assisted patency rates were 86% and 95%, and at 4 years the rates were 67% and 87%, respectively (Figs 3 and  4 ). In the univariate and multivariate models, the following variables were excluded as independent predictors of shunt dysfunction: sex, age, Child-Pugh class, aetiology of liver disease, bilirubin levels, alanine transaminase, albumin, platelet count and prothrombin time.
Discussion
Failure to improve survival, increased incidence of shunt dysfunction and PSE limit the use of TIPS as the method of choice for the prevention of recurrent variceal bleeding. 8,15 -23 Elective TIPS was, however, found to be more effective than EST in the present study for the prevention of recurrent variceal bleeding; it also improved survival and was associated with a similar rate of PSE.
Variceal rebleeding was significantly more frequent in patients who received EST compared with TIPS, which accords with the results of seven of the eight previous 18 -20,22 -25 In one study, the authors reported significantly higher rates of rebleeding and mortality following TIPS, attributable to the fact that six of the eight patients with post-EST rebleeding required emergency TIPS and that 32 
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patients who could not be stabilized endoscopically within 72 h were excluded from the study. 21 Multivariate regression analysis identified EST as the only significant independent predictor of variceal rebleeding during followup. The difference seems to be due to a reduction in portal pressure following TIPS to below the level required to cause variceal rupture and bleeding. The rebleeding rate in patients treated by EST in the present study agrees with the rates reported by other comparable studies 45.7% versus 47.1% [range 21 -61%]), suggesting that the level of performance of the University Medical Centre Ljubljana, is comparable with that of other centres. 18 -25 The rebleeding rate in the TIPS patients in the present study was lower than the rate in other comparable studies (6.3% versus 19.0% [range 9.1 -40%). 18 -25 The difference may be ascribed to patient selection, as well as to regular ultrasound monitoring of shunt patency and timely and effective additional interventions. Comparable rates of recurrent bleeding following TIPS and following shunt operations (range 3 -8%) suggest a common mechanism, i.e. direct reduction of pressure in the portal system. 26, 27 Rebleeding episodes following TIPS are most commonly due to reduced shunt patency; pseudointimal hyperplasia and neointimal hyperplasia are the most common causes of reduced of shunt patency. 28 Furthermore, factors predicting reduced shunt patency have not been identified, most probably because of the heterogeneity of factors affecting shunt function. In the present study, reduction in shunt patency occurred in 10 patients (20.8%). In the majority of patients, reduction in trans-shunt flow was determined by Doppler ultrasound before the appearance of clinical signs. Previous studies have reported the incidence of shunt dysfunction to be 18 -78%, with the highest repeat intervention rates in studies that used angiography to detect shunt dysfunction. 18,21 -24 Despite the greater number of reinterventions, they failed to lower the rate of recurrent bleeding episodes (14.5% [range 10 -23%). 18,21 -24 Fewer reinterventions (18%) and rebleeding episodes (13%) were reported for patients who, as in the present study, had regular ultrasound monitoring for reduced shunt patency. 20 Shunt dysfunction can be corrected by dilatation or by placement of an additional stent. Due to timely identification of shunt dysfunction and prompt interventions undertaken in patients in the present study, the rate of primary assisted patency at 4 years after TIPS increased to 87.0%.
Similar to previous investigations, the most common cause of death in the present study was liver failure following TIPS placement and recurrent bleeding after EST. 18, 19, 21, 22 The most probable reasons for significantly better 30-day and 4-year survival after elective TIPS compared to EST were lower mortality due to rebleeding after elective TIPS, longer interval between the last bleeding episode and elective TIPS (lower mortality due to liver failure), and short post-EST interval between last bleeding and enrolment in the study (higher mortality due to early rebleeding). Increased mortality due to rebleeding in EST patients in the present study was attributable to the fact that, in previous studies, patients with uncontrolled bleeding following EST were managed by emergency TIPS placement (mean 14.5%; range 4 -28%), 18 -24 which was not the case in the present patient series. Lower mortality rates established in TIPS patients were in accordance with the results of two out of eight previous studies. 18, 24 Multivariate regression analysis of present P Popovič, B Štabuc, P Skok et al. Treatment of recurrent variceal bleeding study data identified that EST and age > 65 years were significant independent predictors of death during follow-up; Child-Pugh classification C almost reached statistical significance as an independent predictor of death. Previous studies have shown that, regardless of the therapy used, survival of patients who have variceal bleeding is related to liver function. 18 -25 This is in keeping with observations from the present study that patients with advanced liver disease had higher mortality rates. Survival of Child-Pugh B and Child-Pugh C patients was better following TIPS than following EST and the difference was statistically significant for Child-Pugh class B liver failure patients. The most frequent causes of death in Child-Pugh class B and Child-Pugh class C patients were rebleeding and liver failure, respectively.
The incidence of PSE following TIPS is not known. The rates reported in the available literature range from 10% to 54%. 8,13,14,18,19,21 -23,29,30 The discrepancy in the reported results is possibly attributable to different definitions of PSE associated with TIPS, as well as to the heterogeneity of the subjects studied, differences in follow-up and PSE evaluation methods, and prophylactic use of lactulose. In comparable studies, 18,19,21 -23 a higher PSE incidence in patients treated by TIPS than in patients undergoing EST has been reported: 29 -54% versus 7 -26%, respectively. Two studies documented similar results for TIPS and EST patients (22.7% versus 25%, and 50% versus 44%). 20, 24 In three studies, 20 -22 procedure-related PSE was defined as new, clinically significant encephalopathy requiring initiation of treatment in a patient with no previous history of PSE, or worsening of pre-existing clinically significant PSE requiring either hospitalization or an increase in therapeutic approach. In four studies, 18, 19, 23, 24 PSE associated with a procedure was defined as a spontaneous episode of clinically-verified PSE. The rate of spontaneous PSE episodes of 34.7% (range 22.7 -54%) reported in the above-mentioned studies was similar to that seen in the present study. Some authors 24 found that TIPS and EST were associated with the same rate of PSE, yet the TIPS patients were given prophylactic lactulose therapy, which was not the case in other studies. Statistically significant differences in the rate of spontaneous PSE episodes following TIPS and EST (33.3% and 37.0%) and in the incidence of PSE associated with TIPS and EST (8.2% and 2.2%) were not observed between the groups in the present study. This similarity in results between the groups may be due to the patients having similar clinical characteristics prior to the procedures being carried out: similar number of patients with severe liver disease, similar number of patients with previous PSE and non-alcoholic liver disease, and similar age of patients in both groups. Another probable reason for a lower PSE incidence following TIPS was most likely a smaller shunt diameter (10 -12 mm). Similarly, Sarfeh et al. 26 noted that PSE incidence, which was 39% for shunts 16 -20 mm in diameter, fell to 9% for portocaval Hshunts measuring only 8 mm. Johansen, 27 who used smaller portocaval shunts (10 -12 mm) in Child-Pugh A and B patients, reported an incidence of PSE of only 6%. Lower rates of PSE observed in the TIPS group are also attributable to haemodynamic stability and compensated liver function in these patients. The literature reports that PSE occurs mostly as a result of alcoholic intake, rebleeding, infection, dehydration or aggressive diuretic therapy and that it disappears with proper diet and therapy without requiring hospital admission, 19,28 -30 which is in line with our experience. Accurate estimates of the incidence and • Received for publication 4 January 2010 • Accepted subject to revision 19 January 2010
• Revised accepted 26 April 2010 Copyright © 2010 Field House Publishing LLP severity of PSE after TIPS placement are precluded by heterogeneity across studies, different definitions of PSE occurring after TIPS, as well as by a number of open questions concerning ammonia metabolism, brain adaptation to neurotoxins produced within the gastrointestinal tract and changes in astrocyte metabolism.
Several conclusions can be made on the basis of the present study. First, the data confirmed initial reports that TIPS can be technically completed safely in patients with advanced liver disease, that it effectively lowers portal pressure and that it was more effective than EST in reducing the occurrence of variceal rebleeding. Secondly, TIPS was found to be associated with a statistically significant improvement in survival. Patients with Child-Pugh classification B treated by TIPS showed significantly better survival rates than EST patients and Child-Pugh C patients treated by TIPS also showed better survival rates. Observations that PSE was a complication in a minority of patients treated by TIPS or EST were confirmed. An additional important observation was that, since shunt dysfunction can develop in patients during follow-up, regular Doppler ultrasound monitoring is required to allow for timely identification of shunt dysfunction and corresponding re-intervention. Adequate trans-shunt flow can be restored by re-intervention, which is safe, effective and not technically demanding. With this proactive approach, recurrent TIPS dysfunction is usually not associated with symptoms of recurrent variceal bleeding.
The main value of elective TIPS is that it effectively prevents variceal rebleeds recurring at short intervals and that it is not only indicated in patients who are candidates for liver transplantation.
